ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Also written as “IBI363”, “IBI363 + bevacizumab” and “IBI363+IBI305”.

Its studies are mostly in Melanoma · Lymphoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms, led by Innovent Biologics.

Drug pageAnti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 20, 202610 company-led studies, 10 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics1010 open or runningphase 3since Jul 20, 2026Jan 9, 2022Nov 30, 2026phase 2 · NCT07122687

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2022First study: phase 1 study in LymphomaFirst studyNCT05290597 · 40 enrolled · Australia
  2. Jul 5, 2022Phase 1 study in LymphomaNCT05460767 · 504 enrolled · China
  3. Oct 7, 2023Phase 2 study in MelanomaNCT06081920 · 180 planned · China
  4. Feb 4, 2024Phase 2 study in MelanomaNCT06281678 · 178 planned · United States
  5. Jun 13, 2024Phase 1 study in Advanced MalignanciesNCT06468098 · 556 planned · China
  6. Jan 22, 2025Phase 2 study in MelanomaNCT06797297 · 203 enrolled · China
  7. Jun 24, 2025Phase 2 study in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 170 planned · China
  8. Aug 7, 2025Phase 2 study in EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerNCT07124793 · 60 planned · China
  9. Jan 16, 2026Phase 2 study in Resectable Stage II-III Non-small Cell Lung CancerNCT07402070 · 10 planned · China
  10. Jul 20, 2026Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07722494 · 550 planned · China
  11. Nov 2, 2026Primary completion moved from 2026-03-31 to 2026-12-31Date moved laterphase 2 · +9 months · NCT06797297

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687
  2. Dec 31, 2026Primary completion: phase 2 study in Resectable Stage II-III Non-small Cell Lung CancerNCT07402070
  3. Dec 31, 2026Primary completion: phase 2 study in MelanomaNCT06797297
  4. Dec 31, 2026Primary completion: phase 1 study in LymphomaNCT05460767

TargetBeta

PDCD1 →read by rule
“A bispecific antibody fusion protein composed of a monoclonal antibody targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722494Colorectal Neoplasms · China3RecruitingOct 31, 2028550
NCT07402070Resectable Stage II-III Non-small Cell Lung Cancer · China2Not yet recruitingDec 31, 202610
NCT07124793EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer · China2Not yet recruitingSep 30, 202660
NCT07122687Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer · China2RecruitingNov 30, 2026170
NCT06797297Melanoma · China2Active, not recruitingDec 31, 2026203
NCT06468098Advanced Malignancies · China1RecruitingJun 30, 2025556
NCT06281678Melanoma · United States2RecruitingMar 1, 2026178
NCT06081920Melanoma · China2RecruitingOct 19, 2028180
NCT05460767Lymphoma · China1Active, not recruitingDec 31, 2026504
NCT05290597Lymphoma · Australia1Active, not recruitingJan 28, 202640

How it is read

Names in the registry

  • “IBI363”, 7 entries
  • “IBI363 + bevacizumab”, 1 entry
  • “IBI363+IBI305”, 1 entry
  • “IBI363 + chemotherapy”, 1 entry
  • “IBI363 + Investigator's Choice SOC”, 1 entry

Codes read as this program: IBI363.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.